Item 1

Call to order

Item 2

Approval of minutes from November 3, 2017 (Vote required)

Item 3

Old business: Report on Health and Human Services Commission decisions on acceptance of
the Drug Utilization Review (DUR) Board recommendations from the November 3, 2017,
meeting

Item 4 (Part 1 of 2)

New business:

Public comment on drug classes to be reviewed and clinical drug reviews to be reviewed for the
Medicaid Preferred Drug List (PDL):

a. Acne agents, oral (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4a-acne-agents-oralcurrent_
product-listing.pdf)
b. Acne agents, topical (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4b-acne-agents-topical.pdf)
c. Analgesics, narcotic long (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4c-analgesics-narcotic-longacting.
pdf)
d. Analgesics, narcotic short (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4d-analgesics-narcotic-shortacting.
pdf)
e. Angiotensin modulator combinations
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4e-angiotensin-modulators-combinations.pdf)
f. Angiotensin modulators (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4f-angiotensin-modulators.pdf)
g. Antimigraine agents, other (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4g-antimigraine-agents-othercurrent-
product-listing.pdf)
h. Antimigraine agents, triptans (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4h-antimigraine-agentstriptans.
pdf)
i. Bladder relaxant preparations
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4i-bladder-relaxants-preparations.pdf)
j. H. pylori treatment (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4j-hpylori-treatments.pdf)
k. Immunomodulators, atopic dermatitis
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/012618/4k-immunomodulators-atopic-dermatitis.pdf)
l. Intranasal rhinitis agents (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4l-intranasal-rhinitis.pdf)
m. Movement disorders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4m-movement-disorders.pdf)
n. Neuropathic pain (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4n-neuropathic-pain.pdf)
o. Ophthalmics, anti-inflammatory/immunomodulator
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4o-ophthalmics-antiInflammatoryimmunomodulator.
pdf)
p. Phosphate binders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4p-phosphate-binders.pdf)
q. Platelet aggregation inhibitors
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4q-platelet-aggregation-inhibitors.pdf)
r. Progestins for cachexia (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4r-progestins-for-cachexiaretired.
pdf)
s. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4s-proton-pump-inhibitors.pdf)
t. Smoking cessation (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4t-smoking-cessationagents.
pdf)

Item 4 (Part 2 of 2)

Public comment on new drugs to be reviewed for the Medicaid PDL:
1. Gastrointestinal (GI) motility, chronic / Symproic
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-1-gastointestinal-motility-chronic-symproicndu.
pdf)
2. Glucocorticoids, inhaled / Armonair Respiclick
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-2-glucocorticoids-inhaled-armonair-respiclick.pdf)
3. Glucocorticoids, inhaled / Trelegy Ellipta
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-3-glucocorticoids-inhaled-trelegy-ellipta-ndu.pdf)
4. Glucocorticoids, oral / Zodex (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4-4-glucocorticoids-oralzodex.
pdf)
5. HAE treatments / Haegarda (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4-5-hae-treatmentshaegarda.
pdf)
6. Hypoglycemics, insulin and related agents / Fiasp FlexTouch pen
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-6-hypoglycemics-insulins-fiasp-flextouch-pen.pdf)
7. Hypoglycemics, insulin and related agents / Fiasp vial
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-7-hypoglycemics-insulins-fiasp-vial.pdf)
8. Hypoglycemics, insulin and related agents / Humalog Junior KwikPen
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-8-hypoglycemics-insulins-humalog-juniorkwikpen.
pdf)
9. Stimulants and related agents / Cotempla XR-ODT
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/4-9-stimulants-related-agents-cotempla-xr-odt.pdf)

Item 5

Executive work session
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas
Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may
meet in executive session on one or more items listed under new business as permitted by the
Texas Open Meetings Act.

Item 7

Announcements of drugs recommended for the Medicaid PDL

Item 8

Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC

a. Report on recent retrospective DUR intervention sent for high dose attention deficit
hyperactivity disorder medication management in youth
b. Report on recent retrospective DUR intervention outcomes for GI management
c. Retrospective DUR proposals: (Vote required)
i. Hypertension management
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/8c-i-hypertension-management.pdf)
ii. Major depressive disorder management
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/8c-ii-major-depressive-disordermanagement.
pdf)
iii. Benzodiazepine anxiolytics and controlled sedative hypnotics
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/8c-iii-benzodiazepine-anxiolytics-controlledsedative-
hypnotics.pdf)

Item 9

Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health
Information Designs, LLC (Vote required)

a. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/9a-proton-pumpinhibitors.
pdf)
b. Topical retinoids (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/9b-topical-retinoids.pdf)

Items 10 - 12

10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer,
Pharm. D., University of Texas at Austin College of Pharmacy (Vote required)
a. Fentanyl (inhalation/oral/transdermal)
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/10a-fentanyl.pdf)
b. Gabapentin (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/10b-gabapentin.pdf)
c. Hydrocodone Bitartrate/Hydrocodone Polistirex
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/10c-hydrocodone-bitartrate-hydrocondepolistirex.
pdf)
d. Ivacaftor (Kalydeco®) and Lumacaftor/Ivacaftor (Orkambi®)
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/10d-ivacaftor-lumacaftor-ivacaftor.pdf)
e. Calcineurin Inhibitors - Pimecrolimus (Elidel®), Tacrolimus (Protopic®)
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/
meetings-events/dur/012618/10e-calcineurin-inhibitors-primecrolimustacrolimus.
pdf)
f. Tramadol (Ultram®) (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/10f-tramadol.pdf)

11. Adjourn

12. Next meeting date: April 27, 2018